1. HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study

   • Samia kada Mohammed
   • Oumar Billa
   • Laurent Arnould

   Original Article 30 January 2023 Pages: 343 - 353

   

2. Prognostic effect of subsequent childbirth after the diagnosis of breast cancer using propensity score matching analysis

   • Tomohiro Ochi
   • Atsushi Yoshida
   • Hideko Yamauchi

   Original Article 03 January 2023 Pages: 354 - 363

   

3. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC

   • Jing-Jing Li
   • Yue Yu
   • Jie Ge

   Original Article 19 January 2023 Pages: 364 - 378

   

4. Identification of prognostic genes signature and construction of ceRNA network in pirarubicin treatment of triple-negative breast cancer

   • Jiulong Ma
   • Fengjun Wang
   • Liqun Ren

   Original Article 09 January 2023 Pages: 379 - 392

   

5. Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification

   • Yan Li
   • Feiyang Na
   • Jianying Pei

   Original Article 20 January 2023 Pages: 393 - 411

   

6. Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)

   • Shigeru Imoto
   • Kun Wang
   • Masahiko Nishiyama

   Original Article 23 January 2023 Pages: 412 - 423

   

7. Characterization of protein-based risk signature to predict prognosis and evaluate the tumor immune environment in breast cancer

   • Xin Qing
   • Chunlei Yuan
   • Ke Wang

   Original Article 02 February 2023 Pages: 424 - 435

   

8. ER–/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor

   • Christine Song
   • Ayse Tuba Kendi
   • SeungBaek Lee

   Original Article 01 March 2023 Pages: 436 - 452

   

9. Dynamic network biomarker to determine the critical point of breast cancer stage progression

   • Fa Jiang
   • Lifeng Yang
   • Xiong Jiao

   Original Article 18 February 2023 Pages: 453 - 465

   

10. Severity and risk factors of interval breast cancer in Queensland, Australia: a population-based study

    • Kou Kou
    • Jessica Cameron
    • Peter D. Baade

    Original Article Open access 21 February 2023 Pages: 466 - 477

    

11. Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes

    • Fan Wang
    • Linghui Fang
    • Chen Fan

    Original Article 01 March 2023 Pages: 478 - 488

    

12. Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis

    • Hanxi Zhang
    • Jamie C. Barner
    • Dhatri Kodali

    Original Article 26 February 2023 Pages: 489 - 496

    

13. Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region

    • Nobumoto Tomioka
    • Kanako C. Hatanaka
    • Masato Takahashi

    Original Article Open access 09 March 2023 Pages: 497 - 505

    

14. Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)

    • Kenji Tamura
    • Toru Mukohara
    • Hiroji Iwata

    Original Article Open access 29 March 2023 Pages: 506 - 517